Exhibit 99.1

SOCIETY PASS INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Currency expressed in United States Dollars (“US$”))

	June 30, 2025			August 15, 2025
	(Unaudited)			(Proforma)(1)
ASSETS
Current assets:
Cash and cash equivalents	$	8,218,805		$	21,009,098
Restricted cash		50,000			50,000
Accounts receivable, net		1,064,164			708,315
Inventories		127,843			127,843
Contract assets		327,267			327,267
Deposits, prepayments and other receivables		12,796,555			6,533,361
Total current assets		22,584,634			28,755,884
Non-current assets:
Intangible assets, net		5,311,177			5,311,177
Goodwill		81,849			81,849
Plant and equipment, net		347,106			347,106
Right of use assets, net		809,329			809,329
Deferred tax assets		58,350			58,350
Total non-current assets		6,607,811			6,607,811
TOTAL ASSETS	$	29,192,445		$	35,363,695
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payables	$	9,581,836		$	2,821,419
Contract liabilities		951,228			951,228
Accrued liabilities and other payables		15,492,850			15,492,850
Due to related parties		12,739			12,739
Operating lease liabilities		432,842			432,842
Loan		24,270			24,270
Total current liabilities		26,495,765			19,735,348
Non-current liabilities
Operating lease liabilities		377,776			377,776
Deferred tax liabilities		69,000			69,000
Total non-current liabilities		446,776			446,776
TOTAL LIABILITIES		26,942,541			20,182,124
COMMITMENTS AND CONTINGENCIES
Convertible preferred shares; $0.0001 par value, 5,000,000 shares authorized, 4,766,500 and 4,766,500 shares undesignated as of March 31, 2025 and December 31, 2024, respectively
Series A shares: 10,000 shares designated; 0 and 0 Series A shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		—			—
Series B shares: 10,000 shares designated; 0 and 0 Series B shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		—			—
Series B-1 shares: 15,000 shares designated; 0 and 0 Series B-1 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		—			—
Series C shares: 15,000 shares designated; 0 and 0 Series C shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively, net of issuance cost		—			—
Series C-1 shares: 30,000 shares designated; 0 and 0 Series C-1 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively, net of issuance cost		—			—
SHAREHOLDERS’ EQUITY (DEFICIT) SURPLUS
Series X Super Voting Preferred Stock, $0.0001 par value, 153,500 shares designated; 153,500 and 153,500 Series X shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		15			15
Common shares; $0.0001 par value, 50,000,000 shares authorized; 5,011,061 and 5,311,061 shares issued and outstanding as of May 31, 2025 and June 30, 2025, respectively		531			536
Subscription receivable		(381,111	)		(381,111	)
Additional paid-in capital		114,698,365			128,248,848
Less: Preferred stock held in treasury, at cost; 150,000 and 150,000 shares at May 31, 2025 and June 30, 2025, respectively		(15	)		(15	)
Less: Common shares held in treasury, at cost; 51,902 and 51,902 shares May 31, 2025 and June 30,2025, respectively		—			—
Accumulated other comprehensive loss		(380,449	)		(380,449	)
Accumulated deficit		(111,488,907	)		(112,091,618	)
Total (deficit) surplus attributable to Society Pass Incorporated		2,448,429			15,396,206
Non-controlling interest		(198,525	)		(214,635	)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIT) SURPLUS		2,249,904			15,181,571
TOTAL LIABILITIES AND EQUITY	$	29,192,445		$	35,363,695

(1) Proforma as adjusted additional paid in capital reflects the net proceeds we expect to receive, after deducting underwriting fee, underwriter expense allowance and other expenses from the initial public offering (the “IPO”) of NusaTrip Incorporated, a subsidiary of the Company (“NusaTrip”). We received net proceeds of approximately $13,500,000 (gross offering proceeds of $15,000,000, less underwriting discounts of $1,050,000, non-accountable expense of 150,000 and offering expenses of $300,000, of which $263,194 have paid) from the IPO. The shares of common stock reflect the issuance and sale of 3,750,000 shares of common stock of NusaTrip at an initial public offering price of $4.00 per share after deducting underwriting discounts, underwriter expense allowance and other expenses.